Y-27632 Dihydrochloride: A Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of ROCK1 and ROCK2 kinases, offering IC₅₀ values of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2, with over 200-fold selectivity over other kinases (APExBIO). It disrupts Rho-mediated stress fiber formation and cytokinesis, modulates stem cell viability, and suppresses tumor invasion in vitro and in vivo. Solubility is high in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL) under standard lab conditions. The compound empowers research in cancer biology and regenerative medicine, and its selectivity minimizes off-target effects compared to other ROCK inhibitors (Precision Targeting of the Rho/ROCK Pathway). Use and storage parameters are well characterized and critical for reproducibility (APExBIO).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are central effectors in the Rho GTPase pathway. They regulate actin cytoskeletal dynamics, cell migration, proliferation, and apoptosis. Dysregulated ROCK signaling is implicated in cancer metastasis, fibrosis, and abnormal smooth muscle contraction. Selective inhibition of ROCK kinases enables targeted study of cytoskeletal remodeling, cell cycle progression, and tumor microenvironment modulation (Di Marzo et al., 2025). Y-27632 dihydrochloride from APExBIO (SKU: A3008) is a benchmark small molecule for dissecting these pathways.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the ATP-binding site in the catalytic domain of ROCK1 and ROCK2. This inhibits kinase activity, blocking phosphorylation of downstream substrates such as myosin light chain (MLC) and LIM kinase (APExBIO). The result is reduced actin-myosin contractility, suppression of Rho-mediated stress fiber and focal adhesion formation, and interference with cytokinesis. This cascade modulates G1/S cell cycle progression and cellular morphodynamics. The compound exhibits >200-fold selectivity for ROCK1/2 over kinases like PKC, MLCK, and PAK, minimizing off-target signaling noise. In smooth muscle and epithelial cells, this manifests as reduced contractility and enhanced cell survival under stress.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM in biochemical assays (APExBIO).
• It exhibits >200-fold selectivity versus PKC, MLCK, cAMP-dependent protein kinase, and PAK, minimizing off-target interference (APExBIO).
• Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, at room temperature (25°C) (APExBIO).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (Smith 2023, DOI).
• Inhibits tumor invasion and metastasis in mouse models of cancer, as measured by histopathology and invasion assays (Di Marzo et al., 2025, DOI).
• Enhances survival and clonal expansion of stem cells in organoid and 3D culture systems (see also Optimizing Cell Assays with Y-27632 dihydrochloride).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely deployed in:

• Stem cell research: Enhances viability and expansion of human embryonic and induced pluripotent stem cells.
• Cancer biology: Suppresses invasion, metastasis, and pathological structure formation in in vivo tumor models.
• Cytoskeletal studies: Disrupts Rho-mediated stress fiber formation and focal adhesion assembly.
• Cell proliferation assays: Used to modulate G1/S transition and analyze cell cycle checkpoints.

This article expands on the strategic application guidance discussed in Precision Targeting of the Rho/ROCK Pathway by providing granular solubility and storage parameters, ensuring reproducibility across model systems.

Common Pitfalls or Misconceptions

• Overgeneralization: Y-27632 dihydrochloride does not inhibit all Rho-associated processes—its effect is selective for ROCK1/2 and does not block upstream Rho GTPase activity.
• Solubility assumptions: Solubility is temperature- and solvent-dependent; suboptimal preparation can lead to precipitation or inaccurate dosing.
• Storage stability: Stock solutions at -20°C are stable for several months, but long-term storage of reconstituted solutions is discouraged due to hydrolysis risk.
• Model limitations: In vivo efficacy and safety are species- and context-specific; not all tumor or tissue types respond equivalently.
• Off-target effects: At concentrations above recommended ranges, non-ROCK kinases may be affected.

Workflow Integration & Parameters

For optimal experimental performance, Y-27632 dihydrochloride should be prepared at recommended solvent concentrations: DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL). Use gentle warming (37°C) or ultrasonic bath to aid dissolution. Store solid at 4°C (desiccated); stock solutions at -20°C for up to several months. Avoid repeated freeze-thaw cycles and long-term storage of solutions. Typical working concentrations for cell-based assays are in the 1–10 μM range, but must be empirically optimized for each cell type and assay. Inclusion of vehicle-only controls is essential for robust data interpretation (Optimizing Cell Assays with Y-27632 dihydrochloride; this article clarifies solvent stability versus that prior overview).

For translational workflows, researchers should cross-validate results with other ROCK inhibitors and evaluate off-target pathways. Refer to Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cancer Research for comparative benchmarks; this current article provides more detailed mechanistic and solubility criteria.

Conclusion & Outlook

Y-27632 dihydrochloride, supplied by APExBIO, remains a cornerstone tool for precise, selective ROCK inhibition in modern cell biology and cancer research. Its validated selectivity, solubility, and workflow integration enable reproducible modulation of cytoskeletal, proliferative, and invasive cellular phenotypes. Future research may expand its translational utility and further refine its application in regenerative medicine and disease modeling. For detailed protocols and ordering, see the official Y-27632 dihydrochloride product page.